For instance, cohort 1 of the Morpheus phase Ib/II trial is exploring several innovative drugs in combination with the approved atezolizumab–bevacizumab combination, namely, RO7247669 (an anti-PD-1/LAG3 bispecific antibody), tiragolumab (an anti-TIGIT antibody), tocilizumab (an anti-IL-6 receptor antibody), SAR439459 (a pan-TGFβ inhibitor), or TPST-1120 (a first-in-class, oral selective PPARα antagonist), to enhance the anti-tumor immune response (NCT04524871). This evidence concerns the gene LAG3 and neoplasm.